Wire · opportunities
Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 28 August 2026 · Fusion42 review
Teva Pharmaceuticals has made a proposed acquisition offer for BioXcel Therapeutics' novel dexmedetomidine sublingual film, a neuroscience product under FDA review for at-home treatment of agitation in schizophrenia and bipolar disorders. The acquisition, subject to bankruptcy court approval and potential higher bids, aims to expand Teva’s psychiatry portfolio pending FDA approval.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.
◆ ◆ The Wire takeaway
You face a market opening as the first FDA-approved at-home treatment for severe agitation is poised to enter the psychiatry space, creating new therapy options outside hospitals. Psychiatry drug founders should prepare for heightened competition and patient demand shifts with Teva’s expanded portfolio.
◆ Coverage
2 sources · 28 Aug 2026
◆ Related on Wire
◆ Topics